Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
US Army
Queensland Health
McKinsey
Teva
Covington
Accenture
Harvard Business School

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021880

« Back to Dashboard

NDA 021880 describes REVLIMID, which is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are twenty-three patents protecting this drug and three Paragraph IV challenges. Additional details are available on the REVLIMID profile page.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lenalidomide profile page.
Summary for 021880
Tradename:REVLIMID
Applicant:Celgene
Ingredient:lenalidomide
Patents:23
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 021880
Generic Entry Date for 021880*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 021880
Suppliers and Packaging for NDA: 021880
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REVLIMID lenalidomide CAPSULE;ORAL 021880 NDA Celgene Corporation 59572-402 59572-402-00 100 CAPSULE in 1 BOTTLE (59572-402-00)
REVLIMID lenalidomide CAPSULE;ORAL 021880 NDA Celgene Corporation 59572-402 59572-402-28 28 CAPSULE in 1 BOTTLE (59572-402-28)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Dec 27, 2005TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 17, 2018
Regulatory Exclusivity Use:EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
Regulatory Exclusivity Expiration:Feb 17, 2022
Regulatory Exclusivity Use:FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
Regulatory Exclusivity Expiration:Jun 5, 2020
Regulatory Exclusivity Use:TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

Expired US Patents for NDA 021880

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-005 Dec 21, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-002 Dec 27, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-006 Jun 5, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim
US Department of Justice
AstraZeneca
QuintilesIMS
Healthtrust
Cerilliant
Harvard Business School
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.